Combination therapy

Delve into the world of Combination therapy in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Combination therapy to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Novo Nordisk Licenses Nanexa's PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes
CompanyDeals

Novo Nordisk Licenses Nanexa’s PharmaShell Platform in Up to EUR 1.165 Billion Global Deal – Targeting Monthly and Quarterly Long‑Acting Injectables for Obesity and Type 2 Diabetes

Nanexa AB (STO: NANEXA), a Swedish drug delivery platform company, announced a global exclusive license and collaboration agreement with Novo Nordisk (NYSE: NVO) for the use of the PharmaShell technology…

European Commission Revokes Hansoh's Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

European Commission Revokes Hansoh’s Aumolertinib Marketing Authorization – EU Approval Reversed Seven Months After Grant in TAGRISSO Data‑Protection Dispute

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval

CompanyDrug

Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment

CompanyDrug

Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment

CompanyDrug

Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting

CompanyDrug

BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination

CompanyDrug

JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC

CompanyDrug

Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023

CompanyDeals

Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda

Show More